Skip to content

Study · Randomized controlled trial · n = 23 · 2010

1 result

Do the actions of glucagon-like peptide-1 on gastric emptying, appetite, and food intake involve release of amylin in humans?

Asmar M, Bache M, Knop FK, Madsbad S, Holst JJ

The Journal of clinical endocrinology and metabolism1 Mar 2010Cited by 34 (Europe PMC)

PMID20194711 (opens in a new tab)DOI10.1210/jc.2009-2133 (opens in a new tab)PepBankPUB-20194711
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In people with type 1 diabetes and healthy controls, pramlintide infusion had effects similar to human amylin infusion.

    In plain wordsIn people with type 1 diabetes and healthy controls, pramlintide and amylin infusions had similar effects.

    Peptide
    Pramlintide (Symlin)
    Outcome
    Not applicableOverall infusion effects
    Study

    n = 23

    Comparator
    Amylin infusion
    Outcome group
    Receptor activity and mechanism · Whole body
    Studied dose
    Dose not stated · infusion · 270 minAs given in this study (human).

    Source sentences

    Summary
    Amylin and pramlintide infusion had similar effects.
    2 context sentences
    Summary · context
    Eleven C-peptide and amylin-negative patients with type 1 diabetes mellitus (T1DM) and 12 matched healthy controls participated in a placebo-controlled, randomized, single-blinded, crossover study.
    Summary · context
    With glucose clamped between 6 and 9 mm, near-physiological infusions of GLP-1, human amylin, pramlintide, or saline were given for 270 min during and after a fixed meal.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 2 not yet recruiting · source ClinicalTrials.gov (opens in a new tab)

Not yet recruitingNot applicableNCT07340775

Hypersensitivity to Amylin in Post-Traumatic Headache

Danish Headache Centern = 21est. Feb 2026 to est. Dec 2028

Headache Disorders, Secondary · Brain Diseases · Headache Disorders · Nervous System Diseases · Central Nervous System Diseases · Neurologic Manifestations · Signs and Symptoms · Pathological Conditions, Signs and Symptoms · Post-Traumatic Headache · Pain · Peptide Hormones · Hormones · Hormones, Hormone Substitutes, and Hormone Antagonists · Peptides · Amino Acids, Peptides, and Proteins · Amylin · Pramlintide

Trial pageClinicalTrials.govUpdated 14 Jan 2026
Not yet recruitingNot applicableNCT07340788

Amylin-Induced Migraine Attacks Without Aura

Danish Headache Centern = 21est. Feb 2026 to est. 30 Oct 2028

Headache Disorders, Primary · Headache Disorders · Brain Diseases · Nervous System Diseases · Central Nervous System Diseases · Neurologic Manifestations · Signs and Symptoms · Pathological Conditions, Signs and Symptoms · Migraine Disorders · Headache · Pain · Peptide Hormones · Hormones · Hormones, Hormone Substitutes, and Hormone Antagonists · Peptides · Amino Acids, Peptides, and Proteins · Amylin · Pramlintide

Trial pageClinicalTrials.govUpdated 14 Jan 2026

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.